Actively Recruiting
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Led by Crinetics Pharmaceuticals Inc. · Updated on 2026-05-11
150
Participants Needed
24
Research Sites
192 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
CONDITIONS
Official Title
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a histological diagnosis of metastatic or locally advanced inoperable neuroendocrine tumor, neuroendocrine carcinoma, or other solid tumors with confirmed radiological progression
- Have one or more measurable disease locations per RECIST version 1.1
- Have a tumor that expresses somatostatin receptor confirmed by somatostatin receptor imaging
- Have an ECOG performance status of 0, 1, or 2
You will not qualify if you...
- Have tumor progression while undergoing peptide receptor radionuclide therapy (PRRT) or within 6 months after completing PRRT
- Have brain metastases unless asymptomatic and stable for at least one month (for small or large cell lung cancer) or at least 3 months (for other non-neuroendocrine tumors)
- Use anticancer agents within specified intervals before the first dose of study drug
- Had surgery, chemoembolization, or radiofrequency ablation within 90 days before the first dose of study drug
- Participated in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug
- Have carcinoid syndrome
- Have any other active or recently treated malignancy within 3 years, excluding treated cervical intraepithelial neoplasia, superficial bladder cancer, and non-melanoma skin cancer
- Have prior treatment with MMAE
- Have hypersensitivity or history of anaphylactic reaction to octreotide, other somatostatin analogs, or MMAE
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
Crinetics Study Site
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
Crinetics Study Site
Duarte, California, United States, 91010
Actively Recruiting
3
Crinetics Study Site
Newport Beach, California, United States, 92663
Actively Recruiting
4
Crinetics Study Site
Orange, California, United States, 92868
Actively Recruiting
5
Crinetics Study Site
San Francisco, California, United States, 60637
Actively Recruiting
6
Crinetics Study Site
Denver, Colorado, United States, 80218
Actively Recruiting
7
Crinetics Study Site
New Haven, Connecticut, United States, 48201
Actively Recruiting
8
Crinetics Study Site
Atlanta, Georgia, United States, 30322
Actively Recruiting
9
Crinetics Study Site
Lexington, Kentucky, United States, 40536
Actively Recruiting
10
Crinetics Study Site
Metairie, Louisiana, United States, 70006
Actively Recruiting
11
Crinetics Study Site
Detroit, Michigan, United States, 48201
Actively Recruiting
12
Crinetics Study Site
Grand Rapids, Michigan, United States, 49503
Actively Recruiting
13
Crinetics Study Site
Rochester, Minnesota, United States, 53905
Actively Recruiting
14
Crinetics Study Site
Philadelphia, Pennsylvania, United States, 19111
Actively Recruiting
15
Crinetics Study Site
Austin, Texas, United States, 78758
Actively Recruiting
16
Crinetics Study Site
Houston, Texas, United States, 70030
Actively Recruiting
17
Crinetics Study Site
Irving, Texas, United States, 75039
Actively Recruiting
18
Crinetics Study Site
Salt Lake City, Utah, United States, 84112
Actively Recruiting
19
Crinetics Study Site
Charlottesville, Virginia, United States, 22908
Actively Recruiting
20
Crinetics Study Site
Fairfax, Virginia, United States, 22031
Actively Recruiting
21
Crinetics Study Site
Barcelona, Spain, 08023
Actively Recruiting
22
Crinetics Study Site
Barcelona, Spain, 08035
Actively Recruiting
23
Crinetics Study Site
Madrid, Spain, 28040
Actively Recruiting
24
Crinetics Study Site
Madrid, Spain, 28041
Actively Recruiting
Research Team
C
Crinetics Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here